Grand Pharmaceutical Group (FRA:MX6A) Shares Outstanding (EOP): 3,502 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MX6A Grand Pharmaceutical Group Ltd FRA:MX6A
86 GF Score
Price €0.57
GF Value €0.63
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Grand Pharmaceutical Group Shares Outstanding (EOP)?

Grand Pharmaceutical Group FRA:MX6A +1.80% 86 Shares Outstanding (EOP) is 3,502 Mil as of Dec. 2025. GuruFocus rates FRA:MX6A with a GF Score™ of 86/100 and a GF Value™ of €0.63 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Grand Pharmaceutical Group's shares outstanding for the quarter that ended in Dec. 2025 was 3,502 Mil.

Grand Pharmaceutical Group's quarterly shares outstanding stayed the same from Jun. 2025 (3,502 Mil) to Dec. 2025 (3,502 Mil).

Grand Pharmaceutical Group's annual shares outstanding stayed the same from Dec. 2024 (3,502 Mil) to Dec. 2025 (3,502 Mil).


Grand Pharmaceutical Group  (FRA:MX6A) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Grand Pharmaceutical Group Shares Outstanding (EOP) Related Terms


Grand Pharmaceutical Group Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Grand Pharmaceutical Group's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Pharmaceutical Group Shares Outstanding (EOP) Chart

Grand Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,549.57 3,549.57 3,501.81 3,501.81 3,501.81

Grand Pharmaceutical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,501.81 3,501.81 3,501.81 3,501.81 3,501.81

FRA:MX6A vs ZTS, UTHR: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grand Pharmaceutical Group Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Shares Outstanding (EOP) falls into.


FRA:MX6A
86GF Score
Grand Pharmaceutical Group Ltd FRA:MX6A
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grand Pharmaceutical Group Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 3,502 Mil mean?
Grand Pharmaceutical Group (FRA:MX6A) has a Shares Outstanding (EOP) of 3,502 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Grand Pharmaceutical Group and its competitors.
Is Grand Pharmaceutical Group's Shares Outstanding (EOP) too high?
Grand Pharmaceutical Group's current Shares Outstanding (EOP) is 3,502 Mil. Overall, Grand Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's Shares Outstanding (EOP) compare to ZTS and UTHR?
Grand Pharmaceutical Group's Shares Outstanding (EOP) of 3,502 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Grand Pharmaceutical Group and its competitors. Grand Pharmaceutical Group's current Shares Outstanding (EOP) is 3,502 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Grand Pharmaceutical Group (FRA:MX6A) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.63, compared to a current price of €0.57 — trading 10.3% below its estimated fair value. The current Shares Outstanding (EOP) is 3,502 Mil. Grand Pharmaceutical Group's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Grand Pharmaceutical Group (FRA:MX6A), the current Shares Outstanding (EOP) is 3,502 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grand Pharmaceutical Group (FRA:MX6A) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Pharmaceutical Group stock appears to be undervalued. The current stock price of €0.57 is trading 10.3% below its estimated GF Value™ of €0.63. GuruFocus considers Grand Pharmaceutical Group to be Modestly Undervalued.

Key valuation signals for FRA:MX6A:

  • Shares Outstanding (EOP): 3,502 Mil
  • GF Value™: €0.63 vs. price of €0.57 (10.3% below fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the FRA:MX6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grand Pharmaceutical Group Business Description

Other Exchanges 00512:Hong Kong
Address 99 Queen\'s Road Central, Units 3302, 33rd Floor, The Center, Hong Kong, HKG
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
86GF Score

Get the complete analysis for FRA:MX6A

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.57
Price
€0.63
GF Value